Medpace (MEDP)
(Delayed Data from NSDQ)
$356.40 USD
+13.51 (3.94%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $357.00 +0.60 (0.17%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$356.40 USD
+13.51 (3.94%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $357.00 +0.60 (0.17%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
Zacks News
STERIS (STE) Q4 Earnings Surpass Estimates, Gross Margin Rises
by Zacks Equity Research
Robust performances across all four reporting segments drive STERIS' (STE) fiscal fourth-quarter revenues.
Globus Medical (GMED) Q1 Earnings Miss Estimates, Margins Dip
by Zacks Equity Research
According to Globus Medical (GMED), its Q1 results reflect modest revenue growth against a difficult prior-year comparison, coupled with COVID-related revenue impacts in key countries.
Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.
Here's Why You Should Hold on to Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) on favorable international Dental business trends and bullish guidance.
Here's Why You Should Hold on to CVS Health (CVS) For Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) better-than-expected results and strong retail sales.
National Vision (EYE) Tops Q1 Earnings Estimates, Cuts '22 View
by Zacks Equity Research
National Vision (EYE) reports better-than-expected earnings and an increase in store count for the first quarter.
SmileDirectClub (SDC) Q1 Earnings Lag Estimates, Margins Fall
by Zacks Equity Research
SmileDirectClub's (SDC) revenues declined year over year in the first quarter due to a drop in unique aligner shipments.
Charles River (CRL) DSA Arm Prospers, Currency Headwind Stays
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Zimmer Biomet's (ZBH) Procedure Volume Grows, Costs Rise
by Zacks Equity Research
Zimmer Biomet's (ZBH) recently completed the spin-off of the non-core dental and spine business is expected to prove strategic.
Insulet (PODD) Q1 Earnings Surpass Estimates, Margins Grow
by Zacks Equity Research
Robust adoption of Omnipod DASH and record new customer starts have contributed to Insulet's (PODD) Q1 performance.
Medtronic (MDT) Global Business Gains Ground, Volume Woes Stay
by Zacks Equity Research
Since the start of fiscal 2022, Medtronic (MDT) has been witnessing a strong recovery and displayed a return to growth.
Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down
by Zacks Equity Research
Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.
Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Illumina (ILMN) ended the first quarter with better-than-expected earnings and revenues on strength in Core Illumina and the GRAIL businesses driving the top line.
Phibro (PAHC) Q3 Earnings Lag Estimates, 2022 Revenue View Up
by Zacks Equity Research
In Q3, Phirbo (PAHC) reports growth in the Animal Health business on higher sales of processing aids, which are used to improve production efficiency in the ethanol fermentation industry.
Thermo Fisher (TMO) End Markets Strong, Margin Under Pressure
by Zacks Equity Research
Thermo Fisher's (TMO) core business strength was broad-based across segments, end markets, and geographies.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Revenue growth across the BSI and BEST businesses drove Bruker's (BRKR) first-quarter 2022 revenues.
Tandem Diabetes (TNDM) Q1 Earnings Lag Estimates, Sales View Up
by Zacks Equity Research
Robust pump shipments and growth in the installed customer base are driving Tandem Diabetes' (TNDM) first-quarter top line.
Cardiovascular Systems' (CSII) Q3 Earnings Top Estimates
by Zacks Equity Research
Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.
NuVasive (NUVA) Q1 Earnings Beat Estimates, 2022 View Up
by Zacks Equity Research
Robust sales performance across all U.S. product lines drove NuVasive's (NUVA) Q1 top line.
Charles River (CRL) Q1 Earnings Top, Gross Margin Falls
by Zacks Equity Research
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.
CVS Health (CVS) Q1 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
CVS Health (CVS) reports better-than-expected results for Q1, with robust segmental performance driving the top line.
IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.
Here's Why You Should Hold on to Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) given the strong demand for its RESILIA tissue valves and the PASCAL system.
Henry Schein (HSIC) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Robust performances by all three operating segments drove Henry Schein's (HSIC) first-quarter 2022 revenues.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust sales performance across Omnicell's (OMCL) operating segments has contributed to the first-quarter top line.